Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

J-P Ortonne, A Taïeb, A D Ormerod, D Robertson, J Foehl, R Pedersen, C Molta, B Freundlich

Research output: Contribution to journalArticlepeer-review

51 Citations (Scopus)


BACKGROUND: Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses. OBJECTIVES: To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment. PATIENTS AND METHODS: A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of <or = 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined. RESULTS: A total of 187 (83%) patients recaptured the target clinical response of a PGA of <or = 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment. CONCLUSIONS: In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care.
Original languageEnglish
Pages (from-to)1190-1195
Number of pages6
JournalBritish Journal of Dermatology
Issue number5
Early online date21 May 2009
Publication statusPublished - Nov 2009


  • adult
  • female
  • humans
  • immunoglobulin G
  • immunosuppressive agents
  • male
  • middle aged
  • patient satisfaction
  • psoriasis
  • receptors, tumor necrosis factor
  • recurrence
  • retreatment
  • efficacy
  • etanercept
  • re-treatment


Dive into the research topics of 'Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept'. Together they form a unique fingerprint.

Cite this